Imaging the Vesicular Acetylcholine Transporter Using 18F-FEOBV PET in Parkinsons Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03554551|
Recruitment Status : Not yet recruiting
First Posted : June 13, 2018
Last Update Posted : July 11, 2018
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Imaging the Vesicular Acetylcholine Transporter Using 18Fluoro-fluoroethoxybenzovesamicol (18F-FEOBV) Positron Emission Tomography(PET) in Parkinsons Disease|
|Estimated Study Start Date :||August 1, 2018|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||March 31, 2021|
Patients with Parkinsons disease
Disease duration > 4 years, Hoehn & Yahr stage 2-3, 50-85 years old
- Density of vesicular acetylcholine transporter [ Time Frame: Day 1 ]Average density will be determined in each group for intestine, pancreas, suprarenal gland, heart and relevant areas of the brain. Group differences will be calculated
- Correlation to measurements of gastrointestinal denervation [ Time Frame: Day 1 ]Density of vesicular acetylcholine transporter will be correlated to symptoms of gastrointestinal autonomic denervation (constipation, gastroparesis).
- Correlation to measurements of dysautonomia [ Time Frame: Day 1 ]Density of vesicular acetylcholine transporter will be correlated to measurements of dysautonomia (orthostatic hypotension, colon transit time)
- Correlation to measurements of neuropsychological tests [ Time Frame: Day 1 ]Cerebral density of vesicular acetylcholine transporter is correlated with neuropsychological test scores.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03554551
|Contact: Jacob Horsager, M.D.||+email@example.com|
|Contact: Per Borghammer, MD, DMSc, PhDfirstname.lastname@example.org|